Document:

EX-10.2

 Exhibit 10.2 

Nabriva Therapeutics AG 

Amended and Restated Stock Option Plan 2015 

I. INTRODUCTION 
  

	(A)	On April 2, 2015 the shareholders, the Management Board and the Supervisory Board of Nabriva Therapeutics AG (Nabriva or the Company) resolved to implement a stock option plan under
which the Company’s employees, including members of the Management Board, and members of the Supervisory Board are eligible to receive options to purchase Shares of the Company (any recipient of an award of options, a
Beneficiary). On 30 June 2015 the shareholders of the Company resolved to amend the stock option plan so implemented by approving this Amended and Restated Stock Option Plan 2015 (the amended and restated plan, as it may be
amended from time to time, the SOP 2015). 

  

	(B)	Options granted hereunder entitle each Beneficiary to acquire Shares in Nabriva or otherwise settle the options under the conditions set forth herein. Nabriva believes that this SOP 2015 enhances the commitment of
the Beneficiaries to contribute to Nabriva’s success by allowing them to participate in the increase in the value of the Company and thereby aligns the interests of the Beneficiaries with those of the Company’s shareholders.

  

	(C)	Each Beneficiary will receive an Accession Statement (the form of which is attached hereto at Annex ./2) informing the Beneficiary of the SOP 2015 and any awards made to the Beneficiary under it. The
provisions set forth herein regulate the SOP 2015 in its entirety. If any of the information communicated to the potential participants of the SOP 2015 diverges from this SOP 2015, the provisions of this SOP 2015 shall prevail.

  

	(D)	Options pursuant to this SOP 2015 are neither granted as remuneration nor as bonus in exchange for the performance of Beneficiaries during a specific period. Rather, the participation in the SOP 2015 and the
vesting of options pursuant to this SOP 2015 constitute a voluntary benefit of the Company. Following the nature of voluntary benefits these are solely granted to foster the motivation and solidarity of all Beneficiaries. 

II. STRUCTURE OF THE STOCK OPTION PLAN 

A. Options 
 Subject to adjustment as set
forth in Clause II.D.13 hereof, options may be granted and vested to all Beneficiaries under the SOP 2015 for up to 95,000 Shares (the Overall Number of Options). The number of Shares subject to any option granted to a Beneficiary is
set forth on such Beneficiary’s Accession Statement. If an option granted under the SOP 2015 expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part or otherwise results in
Shares not being issued, the unused Shares shall again be available for the grant of options. Notwithstanding the date and duration of their participation herein and without prejudice to the provisions of this SOP 2015, no person (whether or
not he or she is already a Beneficiary under the SOP 2015) shall be entitled to (further) options under this SOP 2015 once the Overall Number of Options are granted, taking into account any permitted share recycling as set forth herein, unless
the shareholders of Nabriva resolve upon an increase of the Overall Number of Options. 

	1.	Vesting 

  

	1.1	The period in which granted options are vested in accordance with the SOP 2015 shall be four years (Vesting Period) unless otherwise determined by the Company; except with respect to options awarded
to members of the Supervisory Board, any alternative vesting period determined by the Company must be approved by the Supervisory Board or the Management Board. The Vesting Period with respect to a Beneficiary shall commence on the Date of
Participation. 

  

	 	(i)	Year 1 

 On the last day of the last calendar month of the first year of the Vesting
Period following the Date of Participation, 25% of the options eligible to be vested per Beneficiary shall be vested automatically with that Beneficiary. 
  

	 	(ii)	Year 2, Year 3 and Year 4 

 During the second, third and fourth years of the Vesting
Period following the Date of Participation, the remaining 75% of the options eligible to be vested per Beneficiary shall be vested with that Beneficiary on a monthly pro rata basis (i.e. 2.083% per month). Options eligible to be vested for any
given month in years two, three and four of the Vesting Period will be vested automatically on the last day of each calendar month. 
  

	1.2	Options shall be vested to Beneficiaries taking maternity leave (Maternity Leave Employees) in accordance with this Clause II.A.1, provided that options shall not be vested during the time the Maternity
Leave Employee is on maternity leave 

  

	1.3	For the avoidance of doubt, options vested prior to the Maternity Leave Employee having taken maternity leave shall not be forfeited. 

 

	2.	Exercise Price 

  

	2.1	The exercise price per option shall be equal to 100% of the Fair Market Value per Share on the Date of Participation (the Exercise Price). If the Management Board, Supervisory Board, or shareholders, as
the case may be, approve the grant of an option with an Exercise Price to be determined on a future date, the Exercise Price shall be equal to 100% of the Fair Market Value on such future date. 

 

	2.2	Subject to the provisions set forth herein, each vested option entitles a Beneficiary to acquire one Share at the Exercise Price. 

  

	2.3	The Company shall pay for any costs arising in connection with the determination of the Exercise Price. 

  

	3.	Exercising vested options 

  

	3.1	Options granted under the SOP 2015 shall have a term of no more than 10 years from the Date of Participation. 

  

	3.2	 Unless otherwise specifically permitted in the Accession Statement or resolved upon by the Management Board with the approval of the Supervisory
Board, the exercise of a vested option is only permissible in case of a Liquidity Event or following an initial public offering occurring during the term of the option. In the case of a Liquidity Event occurring prior to an initial public offering
of the Company, the Beneficiaries are entitled to exercise their vested options, taking into account any vesting acceleration provided for under Clause II.B.8 

	 	
hereof, within the six-week period commencing the day after notification of all Beneficiaries of the upcoming Liquidity Event; provided that, if the acquiring or succeeding corporation (or an
affiliate thereof) assumes any options in the Liquidity Event, such assumed options may be exercised, to the extent vested in accordance with their terms and Clause II.B.8 hereof, at any time during the remaining term of the option while the
Beneficiary is providing services to the acquiring or succeeding corporation (or an affiliate thereof) and within the three-month period following a termination of the Beneficiary’s services to such entity due to a Good Leaver Event. In the
case of an initial public offering, the Beneficiaries are entitled to exercise their vested options at any time, following such offering, during the remaining term of the option while the Beneficiary is providing services to the Company and within
the three month period following a termination of the Beneficiary’s services due to a Good Leaver Event. The period during which an option may be exercised is the Exercise Period. 

 

	3.3	In order to exercise a vested option, the Beneficiary must notify the Company by submitting an exercise notice to the Company in the form of Annex ./3 (the Exercise Notice) one week (or such shorter
period as is permitted by the Company) prior to the date he wishes to exercise the option as specified in the Exercise Notice. 

  

	3.4	In case of a Liquidity Event, the Beneficiaries will – following their exercise of options – only receive a portion of the remainder, if any, of the proceeds from such Liquidity Event after satisfaction of the
holders of certain preferred shares pursuant to liquidation preference agreements as in force at the date of exercise of options, whereas the Beneficiaries will participate in such remainder, if any, pro rata corresponding to their
shareholding in the Company (in case Shares would have been transferred to the Beneficiaries); whereas the Company in case of a distributable remainder in its sole discretion may opt to provide the Beneficiaries with Shares in the Company rather
than with cash amounts. A Beneficiary’s obligation to deposit the Exercise Price shall be subject to notification by the Company that a distributable remainder exists. 

 

	4.	Rights and restrictions attached to vested options 

  

	4.1	The Beneficiaries shall not be entitled to transfer vested options, except to individuals by way of inheritance or bequest. For the avoidance of doubt, Beneficiaries shall also not be entitled to transfer vested options
by virtue of bilateral legal transactions causa mortis with or without consideration. 

  

	4.2	The Beneficiaries shall not be entitled to grant rights to, encumber or dispose of vested options in any other manner (in particular pledge, transfer by way of security or derivative transactions having the same
commercial effect). 

  

	4.3	Options do not entitle the Beneficiary to exercise any shareholder rights. The Beneficiary may only exercise shareholder rights if and to the extent he holds Shares. 

 

	4.4	In the event of an Insolvency of a Beneficiary, the options not yet exercised by such Beneficiary shall automatically be forfeited. 

  

	4.5	Any options not exercised by the end of the Exercise Period shall automatically and finally lapse and be forfeited. 

B. Termination of Employment or Board Position 

In case a Beneficiary’s services to the Company are terminated, the following shall apply: 

	5.	Good Leaver Events 

  

	5.1	If a Beneficiary’s service or employment relationship ends during the term of the SOP 2015 due to (and each of the following a Good Leaver Event) 

 

	 	(i)	retirement due to age or permanent disability (Ausscheiden aufgrund Alters oder dauernder Arbeitsunfähigkeit); 

  

	 	(ii)	death; 

  

	 	(iii)	ordinary termination by maintaining the contractual or statutory periods and deadlines (ordentliche Kündigung) by the Company or the Beneficiary; 

 

	 	(iv)	justified premature resignation with immediate effect (berechtigter vorzeitiger Austritt); 

  

	 	(v)	unjustified dismissal (ungerechtfertigte Entlassung); 

  

	 	(vi)	mutual termination (einvernehmliche Auflösung); 

  

	 	(vii)	expiry of a Management Board or Supervisory Board mandate (Nichtverlängerung eines Mandats); 

  

	 	(viii)	premature revocation of a Management Board or Supervisory Board mandate without good cause (Abberufung ohne wichtigen Grund); or 

 

	 	(ix)	resignation of a member of the Management Board or Supervisor Board with good cause (Rücktritt aus wichtigem Grund); 

all rights and entitlements under the SOP 2015 to the options which have not been vested upon the occurrence of a Good Leaver Event shall
be automatically forfeited. For the avoidance of doubt, except as otherwise determined by the Supervisory Board, with respect to members of the Management Board, or the shareholders, with respect to members of the Supervisory Board, none of the
events set forth in (vii), (viii) or (ix) shall constitute a termination of services to the extent the board member continues to provide services to the Company as an employee or otherwise. Options eligible to be vested to a Beneficiary in
a fiscal year which are not actually vested in respect of such Beneficiary in that fiscal year shall not be available to that Beneficiary at any other time. 
  

	5.2	Beneficiaries with options vested but not exercised at the time of a Good Leaver Event shall retain such options and be entitled to exercise such options according to the provisions set forth herein. 

 

	6.	Bad Leaver Events 

  

	6.1	If a Beneficiary’s service or employment relationship with the Company ends during the term of the SOP 2015 due to an event other than a Good Leaver Event (a Bad Leaver Event), all options of the
Beneficiary vested but not exercised at the time a Bad Leaver Event occurs shall be forfeited. The revocation of a member of the Management Board pursuant to a vote of non-confidence by the General Assembly (Vertrauensentzug) shall not
constitute a Bad Leaver Event as long as no reason for justified dismissal is set by the Beneficiary. 

  

	6.2	The Supervisory Board may within its discretion decide whether to grant to a Beneficiary advantages as from a Good Leaver event even though the end of a Beneficiary’s service or employment relationship constitutes
a Bad Leaver Event as described in this Clause II.B.6. In case the Beneficiary concerned functions as a member of the Supervisory Board, the shareholders shall decide on the advantages granted to the Beneficiary as set forth above.

	7.	Exercised options 

 The termination of a service or an employment relationship with the
Company shall have no effect on options that were exercised prior to the date of a declaration of termination of the Beneficiary’s services. 
  

	8.	Accelerated Vesting 

 In case a Liquidity Event occurs, all options outstanding under the
SOP 2015 at such time, shall be assumed, or substantially equivalent options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) and any such options that are not yet vested shall continue to become vested in
accordance with the original vesting schedule set forth on the Beneficiary’s original Accession Statement. However, each such option shall be immediately exercisable in full if, on or prior to the first anniversary of the date of the
consummation of the Liquidity Event, the Beneficiary’s services with the Company or the acquiring or succeeding corporation (or an affiliate thereof) is terminated due to a Good Leaver Event. If the acquiring or succeeding corporation (or an
affiliate thereof) refuses to assume or substitute substantial equivalent options in accordance with the first sentence of this Clause II.B.8, then all remaining options not yet vested with a Beneficiary at the time of such Liquidity Event shall
vest with the Beneficiaries with immediate effect. 
 C. Duration, Expiry, Amendments to and Termination of 
the Stock Option Plan

  

	9.	Duration and Expiry 

  

	9.1	The SOP 2015 shall become effective on upon the registration of the conditional capital increase of the Company resolved upon in the shareholders’ meeting on 30 June 2015 with the commercial register (the
Effective Date). 

  

	9.2	No options shall be granted under the SOP 2015 after the expiration of 10 years from the Effective Date, but options previously granted may extend beyond that date. 

 

	10.	Amendments 

  

	10.1	The Management Board, Supervisory Board or shareholders, as the case may be, may amend, modify or terminate any outstanding option. The Beneficiary’s consent to such action shall be required unless (i) the
Management Board, Supervisory Board or shareholders, as the case may be, determine that the action, taking into account any related action, does not materially and adversely affect the Beneficiary’s rights under the SOP 2015 or (ii) the
change is permitted under Clause II.D.13. 

  

	10.2	The Management Board may amend, suspend or terminate the SOP 2015 or any portion thereof at any time; provided that if at any time the approval of the Company’s shareholders is required, including by
application of Austrian law, the Management Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the SOP 2015 adopted in accordance with this Clause II.C.10.2 shall
apply to, and be binding on the Beneficiaries of, all options outstanding under the SOP 2015 at the time the amendment is adopted, provided the Management Board or shareholders, as the case may be, determine that such amendment, taking into account
any related action, does not materially and adversely affect the rights of Beneficiaries under the SOP 2015. 

	11.	Termination 

 The Company may terminate any option granted to a Beneficiary under the SOP
2015 for good cause if that Beneficiary breaches significant statutory or contractual obligations in connection with its service or employment relationship with the Company. Such good cause shall be a reason pursuant to sec 75 Austrian Stock Company
Act (Aktiengesetz) for members of the Management Board and the Supervisory Board of the Company and pursuant to sec 27 Austrian Employees Act (Angestelltengesetz) for employees of the Company whereby the revocation of a member of the
Management Board pursuant to a vote of non-confidence (Vertrauensentzug) by the shareholders shall not constitute such good cause in the meaning of this paragraph as long as no reason for justified dismissal is set by the Beneficiary. To the
extent the members of the Management Board are affected, the Supervisory Board shall exercise such termination right. To the extent members of the Supervisory Board are affected, the Company’s shareholders shall be competent to resolve upon
such termination by simple majority. 
 D. Risks 
  

	12.	Risks 

  

	12.1	Neither the Company nor any shareholder of the Company (or any of their officers, employees or consultants) 

  

	 	(i)	assumes any responsibility or liability for the development of the value of the market price of the Shares; 

  

	 	(ii)	warrant, assure or guarantee any increase in value of the Shares, in particular it is neither warranted, assured or guaranteed that a Beneficiary will be able to sell his participation in the Company with a profit in
the future nor that no loss will be incurred; 

  

	 	(iii)	warrant, assure or guarantee a profit of a Beneficiary from this SOP 2015; 

  

	 	(iv)	makes any representations or warranty and shall have no liability to the Beneficiary or any other person if any provisions of or payments, compensation or other benefits under the SOP 2015 are determined to constitute
nonqualified deferred compensation subject to Section 409A of the Internal Revenue Code but do not to satisfy the conditions of that section. 

  

	12.2	Each Beneficiary declares with his participation in the SOP 2015 that the participation is voluntary. Each Beneficiary is aware of the fact that he alone bears the risk of a decrease in or total loss of value of
his investments. Each Beneficiary accepts the offer to participate in the SOP 2015 at his own risk and assumes any liability relating thereto. 

  

	12.3	Each Beneficiary is responsible for obtaining legal and tax advice before participating in the SOP 2015 and for evaluating the tax effects connected with the SOP 2015. Each Beneficiary accepts and declares
that he has not been advised by or on behalf of the Company with respect to his participation in the SOP 2015 (in particular regarding legal and tax issues of the participation). 

 

	12.4	The Company declares to undertake the best efforts for a risk minimal and tax efficient settlement of this SOP 2015. 

 D. Miscellaneous 
  

	13.	Stock Adjustments 

  

	13.1	If, during the term of the SOP 2015, changes to the capital of the Company or restructuring measures have an effect on the capital of the Company, such as a stock split or reverse split of stocks, (together
Stock Adjustments) which result in a change in the value of the options, the Company is entitled to adjust the price or the amount of the options respectively, to the extent necessary to compensate changes in value (but not a dilution
of shareholding) resulting from any Stock Adjustments. For the avoidance of doubt, this Clause II.D.13 shall not apply to measures, such as future financing rounds, in which new shareholders of the Company are introduced. 

 

	13.2	The Supervisory Board decides on an adjustment based on a proposal by the Management Board. After execution of the Stock Adjustments the total value of the granted options shall equal the total value of the options
before execution of such Stock Adjustments. The Company will inform the Beneficiaries about the Stock Adjustment and the effective date of the Stock Adjustment. 

  

	14.	Agreement in connection with an Initial Public Offering 

  

	14.1	Each Beneficiary agrees, in connection with the initial underwritten public offering of Shares pursuant to a registration statement under the Securities Act, (i) not to (a) offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or
any other securities of the Company or (b) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of Shares or other securities of the Company, whether any transaction described
in clause (a) or (b) is to be settled by delivery of securities, in cash or otherwise, during the period beginning on the date of the filing of such registration statement with the United States Securities and Exchange Commission and
ending 180 days after the date of the final prospectus relating to the offering (plus up to an additional 34 days to the extent requested by the managing underwriters for such offering in order to address Rule 2711(f) of the National Association of
Securities Dealers, Inc. or any similar successor provision), and (ii) to execute any agreement reflecting clause (i) above as may be requested by the Company or the managing underwriters at the time of such offering. The Company may
impose stop-transfer instructions with respect to the Shares or other securities subject to the foregoing restriction until the end of the “lock-up” period. 

 

	15.	No business practice (“Betriebliche Übung”) 

  

	15.1	The granting of options and the implementation of the SOP 2015 is the free and discretionary choice of the Company, constitutes a voluntary benefit and shall not give rise to any legal claim by a Beneficiary for
the future, not even in the case of repeated granting. 

  

	15.2	Beneficiaries of the SOP 2015 do not have a right for the introduction of another option plan or any vesting of options in addition to those under the SOP 2015, even if the Company implements any other option
plan or vests further options under any other option plan. 

  

	15.3	Vested options under this SOP 2015 do not affect the calculation of severance, premiums, royalties, pension plans or any other remuneration of the Beneficiary. 

 

	16.	Taxes, duties and social contributions 

  

	16.1	 All taxes, social contributions, further duties and costs accrued by the Beneficiary in connection with its participation in the SOP 2015 or due
to the distribution of profits shall be borne by each Beneficiary. Each 

	 	
Beneficiary is obliged to pay taxes relating to the respective options granted/exercised under the SOP 2015 to the competent tax authorities, also in the course of tax audits or any other
procedures. Each Beneficiary shall fully indemnify the Company in respect of all such liabilities and obligations against tax authorities. 

  

	16.2	The employer of the Beneficiary is entitled, if required by statutory law, to withhold wage tax or any other taxes or duties or social contributions to be paid by the Beneficiary. This applies even after termination of
the employment of a Beneficiary with the Company, if the vested options granted are non-lapsable but not yet exercisable. The Company is entitled to demand the full cooperation of the Beneficiary even after his leave with respect to the withholding
of taxes, social contributions, other duties and costs in connection with this SOP 2015. The Beneficiary undertakes to co-operate. 

  

	16.3	Withholdings mentioned above do not release the Beneficiary from his responsibility and obligation to pay all taxes, social contributions, further duties and costs being due and accruing in connection with his
participation in the SOP 2015 or in connection with the distribution of profits. 

  

	17.	Notices 

  

	17.1	Notifications to the Company with respect to the terms of the SOP 2015 shall only be made to: 

Nabriva Therapeutics AG 

Corporate Human Resources 
 fax:
+43 1 74093 1202 
 email: ralf.schmid@nabriva.com 
  

	17.2	Notifications by the Company to the Beneficiary relating to the SOP 2015 shall be made in writing (including email or fax) to each Beneficiary to the respective Beneficiary’s address last disclosed to the
Company. 

  

	18.	Saving provisions 

 If any provision of this SOP 2015 in full or in part is or
becomes invalid, this shall not affect the validity of all other provisions or the valid part of an invalid provision. To the extent legally possible, an agreement shall be made replacing the invalid provision by a provision which best meets the
intent of the terms of the SOP 2015. The same applies to loopholes of the terms of the SOP 2015, which may arise in the course of implementation of the terms of the SOP 2015. 

 

	19.	Governing law and jurisdiction 

 The terms of the SOP 2015, its interpretation and
all rights and obligations arising there from shall be governed by Austrian law, except for international private law and the UN Convention on Contracts for the International Sales of Goods. The courts of Vienna, Austria, shall, to the extent
legally possible, have exclusive jurisdiction regarding all claims in connection with and the terms of the SOP 2015. 
 Annex: 

	./1	Definitions 

	./2	Accession Statement 

	./3	Exercise Notice 

 Annex ./1 

I. Definitions 
  

			
	Bad Leaver Event	  	has the meaning ascribed thereto in Clause II.C.2
		
	Insolvency	  	means the initiation of insolvency proceedings in regard to the assets of a Beneficiary, the dismissal of an application for insolvency due to a lack of assets or the initiation of private insolvency proceedings pursuant to secs.
181 et seq. of the Austrian Insolvency Code (“IO”) or any equivalent rule in any other relevant jurisdiction
		
	Beneficiary	  	is any employee (for the avoidance of doubt including any member of the Management Board), member of the Supervisory Board of the Company or any other individual eligible to receive options hereunder, who receives an award of
options
		
	Company	  	Nabriva Therapeutics AG and its legal successors
		
	Date of Participation	  	means the date on which an option is awarded and the recipient becomes a Beneficiary in this SOP 2015. A Beneficiary’s Date of Participation is set forth on the Beneficiary’s Accession Statement
		
	Effective Date	  	has the meaning ascribed thereto in Clause II.C.9
		
	Exercise Notice	  	has the meaning ascribed thereto in Clause II.A.3
		
	Exercise Period	  	has the meaning ascribed thereto in Clause II.A.3
		
	Exercise Price	  	has the meaning ascribed thereto in Clause II.A.2
		
	Fair Market Value	  	 shall, for each Share for purposes of the SOP 2015, be determined as follows:

 
 (i) if the Shares are not publicly traded, the Management Board, subject to the approval
of the Supervisory Board, will determine the Fair Market Value for purposes of the SOP 2015 on the basis of an enterprise value of the Company of US$148,045,201 as determined by the independent third-party expert evaluator Duff & Phelps B.V. as
of March 31, 2015, and taking into account any measure of value it determines to be appropriate to reflect changes in the value of the Company since March 31, 2015 in a manner consistent with the valuation principles under Section 409A of
the Internal Revenue Code;
  
 (ii) if the Shares trade on a national securities
exchange, the closing sale price (for the primary trading session) on the Date of Participation; or
  

			
		
		  	 (iii) if the Shares do not trade on any such exchange, the average of the closing bid and asked prices as reported by an authorized OTCBB
market data vendor as listed on the OTCBB website otcbb.com) on the Date of Participation.
  

For any date that is not a trading day, the Fair Market Value of a Share for such date will be determined by using the closing sale price or average of the bid
and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the formulas above adjusted accordingly. The Management Board can substitute a particular time of day or other measure of “closing sale
price” or “bid and asked prices” if appropriate because of exchange or market procedures or can, in its sole discretion, use weighted averages either on a daily basis or such longer period as complies with Section 409A of the Internal
Revenue Code.
  
 The Management Board and Supervisory Board have, within the framework
determined by the shareholders in this SOP 2015, sole discretion to determine the Fair Market Value for purposes of the SOP 2015, and all options are conditioned on the Beneficiary’s agreement that the Management Board’s and Supervisory
Board’s determination is conclusive and binding even though others might make a different determination.

		
	Good Leaver Event	  	has the meaning ascribed thereto in Clause II.B.5
		
	Internal Revenue Code	  	means the United States Internal Revenue Code of 1986, as amended or any successor thereto
		
	Liquidity Event	  	 means:
  

(i) an exclusive license of or the sale, the lease or other disposal of all or substantially all of the assets of the Company;

 
 (ii) a sale or other disposal (for the avoidance of doubt, the term disposal shall not
include a pledge) in any transaction or series of transactions to which the Company is a party of 50% or more of the voting power of the Company, other than any transaction or series of transactions principally for bona fide equity financing
purposes in which cash is received by the Company or indebtedness of the Company is cancelled or converted, or a combination thereof;
  

(iii) a merger or consolidation of the Company with or into any third party, other than any merger or consolidation in which the shares of the Company
immediately preceding such merger or consolidation continue to represent a majority of the voting power of the surviving entity immediately after the closing of such merger or consolidation; and

 

			
		
		  	(iv) a liquidation, winding up or any other form of dissolution of the Company.
		
	Management Board	  	means the management board (Vorstand) of the Company
		
	Maternity Leave Employees	  	has the meaning ascribed thereto in Clause II. A
		
	Overall Number of Options	  	has the meaning ascribed thereto in Clause II. A
		
	Securities Act	  	means the United States Securities Act of 1933
		
	Shares and each a Share	  	means the common shares of the Company issued from time to time
		
	SOP 2015	  	has the meaning ascribed thereto in Clause I
		
	Supervisory Board	  	means the supervisory board (Aufsichtsrat) of the Company
		
	Vesting Period	  	has the meaning ascribed thereto in Clause II.A.1

 Annex ./2 

Form of Accession Statement 
 To: 

Ms / Mr [•], 
 [address] 

REF: SOP 2015 / Accession Statement 
 Dear Ms / Mr
[•], 
 You will participate in this SOP 2015 with effect as of [•] (Participation Date). 

As Participant in the SOP 2015 you will be granted options to acquire shares in the Company pursuant to this SOP 2015 in the amounts as set forth in
the Vesting Table attached. 
  
  

Nabriva Therapeutics AG: 
 DATE: 

PARTICIPANT: 
 DATE: 

Annex: 
  

	./	Vesting Table 

 Annex ./3 

Form of Exercise Notice 
 To: 

Nabriva Therapeutics AG  
 Corporate Human Resources 

Leberstraße 20 
 1010 Vienna, Austria 

REF: SOP 2015 / Exercise Notice 
 Dear Sirs, 

I am a participant in the SOP 2015. Capitalized terms not otherwise defined herein shall have the meaning assigned to such term in the SOP 2015. This
is an Exercise Notice. 
 I hereby irrevocably declare to exercise [•] vested options granted to me [on •] 

 

	 	‰	When exercising the above number of options, I wish to acquire [•] Shares as determined in the vesting table attached to my Accession Statement at the Exercise Price per Share. Such Shares shall be delivered to my
securities account no. [•] with [•] against payment in cash by me of the Exercise Price for each Share. I acknowledge that I must satisfy any applicable tax withholding (including social security contributions) resulting from the exercise
of my options by making a cash payment to the Company (or otherwise in a manner as the Company may permit) before any Shares will be delivered to me. 

  

	 	‰	Whereas in the case of a Liquidity Event, (i) I acknowledge that in case of a distributable remainder the Company – in consideration of the Exercise Price – in its sole discretion may opt to provide me
with Shares in the Company rather than with the cash amounts attributable to me according to the SOP 2015, (ii) I shall deposit the Exercise Price only upon notification by the Company that a distributable remainder exists, (iii) upon
such notification, I shall deposit the Exercise Price within seven (7) business days. 

 I acknowledge that options have not been granted
as remuneration or as a bonus for job performance but rather as a voluntary benefit to encourage motivation and solidarity with the Company and that I have no entitlement to any future comparable benefits. 

Name 
 Date 

 ADDENDUM 

with regard to the 
 Nabriva
Therapeutics AG’s 
 Amended and Restated Stock Option Plan 

dated 30 June 2015 

 PREAMBLE 

WHEREAS, on 2 April 2015, the shareholders, Management Board and the Supervisory Board of Nabriva Therapeutics AG (Nabriva or the
Company) resolved to implement a stock option plan under which the Company’s employees and members of the Management Board and the Supervisory Board are eligible to receive options to purchase Shares of the Company; 

WHEREAS, on 30 June 2015, the shareholders of the Company resolved to amend the stock option plan so implemented by approving an amended and restated
version of the stock option plan (the amended and restated plan, the SOP 2015); and 
 WHEREAS, on 22 July 2015, the shareholders of the
Company resolved to amend the SOP 2015 and thus, the Company is interested in amending the SOP 2015 according to such shareholders’ resolution through this addendum to the SOP 2015 (the Addendum). 

 

	1.	INTERPRETATION 

  

	1.1	Definitions 

 Unless explicitly stated otherwise herein, all capitalized terms used in this Addendum
shall have the meaning assigned to them in the SOP 2015. 
  

	1.2	Supplemental 

 Except as explicitly provided herein, the SOP 2015 shall remain in full force and effect,
and the SOP 2015 together with this Addendum shall be read and construed as one document. 
  

	2.	AMENDMENTS TO THE SOP 2015 

  

	2.1	Amendments to Clause II. A 

 (1) Effective as of 22 July 2015, the first paragraph of Clause II. A
(“II. Structure of the Stock Option Plan. A. Options”) of the SOP 2015 shall be deleted and replaced in its entirety by the following: 

Subject to adjustment as set forth in Clause II.D.13 hereof, options (any or all of which may be in the form of Incentive Stock Options) may be granted and
vested to all Beneficiaries (provided that only Company employees are eligible to receive Incentive Stock Options) under the SOP 2015 for up 95,000 Shares (the Overall Number of Options). The number of Shares subject to any option
granted to a Beneficiary is set forth on such Beneficiary’s Accession Statement. If an option granted under the SOP 2015 expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part
or otherwise results in Shares not being issued, the unused Shares shall again be available for the grant of options (subject, however, in the case of Incentive Stock Options to any limitations of the Internal Revenue Code). Notwithstanding the date
and duration of their participation herein and without prejudice to the provisions of this SOP 2015, no person (whether or not he or she is already a Beneficiary under the SOP 2015) shall be entitled to (further) options under this
SOP 2015 once the Overall Number of Options are granted, taking into account any permitted share recycling as set forth herein, unless the shareholders of Nabriva resolve upon an increase of the Overall Number of Options. 

(2) Effective as of the closing of an initial public offering of the Company, the Overall Number of Options shall be increased to 177,499 Shares. 

	2.2	Amendment to Clause II. C.9.2 

 Clause II. C.9.2 shall be deleted and replaced in its entirety by the
following: 
 No options shall be granted under the SOP 2015 after the expiration of 10 years from 22 July 2015, but options previously granted may
extend beyond that date. 
  

	2.3	Amendment to Clause II. D.12.1 

 The following provision shall be added to the end of Clause II. D.12.1:

  

	 	(v)	shall have any liability to a Beneficiary or any other party, if an option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive
Stock Option into an option that no longer qualifies as an Incentive Stock Option. 

  

	2.4	Amendment to Clause II. D.13.1 

 Clause II. D.13.1 shall be deleted and replaced in its entirety by the
following: 
 If, during the term of the SOP 2015, changes to the capital of the Company or restructuring measures have an effect on the capital
of the Company, such as a stock split or reverse split of stocks, (together Stock Adjustments), the Company is entitled to adjust (i) the number and class of securities available under the SOP 2015 and (ii) the price
or the amount of the options respectively, to the extent necessary to compensate changes in value (but not a dilution of shareholding) resulting from any Stock Adjustments. For the avoidance of doubt, this Clause II.D.13 shall not apply to
measures, such as future financing rounds, in which new shareholders of the Company are introduced. 
  

	2.5	Amendment to Annex ./1 I. Definitions: 

 (1) The definition of “Company” shall be deleted and
replaced in its entirety by the following: 
  

	Company	has the meaning ascribed thereto in Clause I.(A); provided that the meaning of Company shall also include Nabriva’s legal successors and, except where the context otherwise requires, Nabriva’s present or
future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a
controlling interest, as determined by the Supervisory Board. 

 (2) The following new definition shall be added: 

 

	Incentive Stock Options	means options that are “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code.EX-10.6

 Exhibit 10.6 

BOARD MEMBER EMPLOYMENT AGREEMENT 

between 
 Nabriva Therapeutics
AG 
 Leberstraße 20 

1112 Vienna 
 AUSTRIA 

represented by the Chair of the Supervisory Board, 

Dr. Denise Pollard-Knight 
 the
“Company” 
 and 

Ralf Schmid 
 Bechardgasse
16/8 
 1130 Vienna 
 AUSTRIA 

the “Board Member” 
 as
follows: 

 I. DUTIES AND RESPONSIBILITIES 

 

	1.	The Board Member has been appointed as a Managing Director of the Company by resolution of the Supervisory Board and has accepted such appointment. 

 

	2.	The Board Member assumes the responsibilities of a member of the Managing Board and additionally as Chief Executive Officer (CEO) of the Company and is entitled to solely represent the Company. 

 

	3.	The Board Member shall fulfill his duties and responsibilities in accordance with the laws of Austria, the Company’s articles of association (the “Articles of Association”), the By-laws of the Management
Board, the resolutions of the Supervisory Board and this Agreement. The Supervisory Board shall further define the duties and responsibility of the Board Member when necessary. 

 

	4.	The Board Member shall perform his duties with the diligence of a reasonable and prudent business man and shall fully dedicate his working capacity to the Company. The Board Member’s principal place of office shall
be at the seat of the Company. The Board Member agrees to travel within Austria and abroad if the business of the company so requires. 

II. TERM 
  

	1.	This Employment Agreement shall become effective as to March 01, 2014 and shall expire on February, 29 2016. This agreement shall replace the Board Member Employment Agreement dated April 30, 2012 (“Previous
Agreement”). Not consumed holidays from the Previous Agreement shall be carried forward to this agreement to the extent that the holiday entitlement is not older than 6 months calculated from the date following the end of the vacation year in
which the entitlement accrued. 

  

	2.	The Supervisory Board of the Company may revoke the Board Member’s appointment for good cause within the meaning of sec 75 para 4 Austrian Stock Corporation Act (Aktiengesetz) prior to the expiry of the term
of appointment. The Company shall be entitled to prematurely terminate this Agreement for reasons which would justify the Board Member’s dismissal under mutatis mutandis application of sec 27 of the Austrian Act on White Collar-Workers.
In case the Company prematurely terminates this Agreement without justified reasons pursuant to sec 27 of the Austrian Act on White Collar-Workers the Board Member is entitled to receive a financial compensation as he would receive in case of
fulfillment. Such payment shall be made as single payment and shall be due at the date of the termination without any discount. The board member shall not be obliged to set off such payments against remuneration gained otherwise. 

III. REMUNERATION 
  

	1.	For his services rendered in accordance with the terms and conditions of this agreement the Board Member shall receive a monthly gross remuneration of EUR 15,000.00 payable fourteen times a year. Whereas the
first twelve installment shall be payable at the end of each month, the 13th and 14th installment shall be due at 31 May and 30 November of
each calendar year. In the case of termination of this Agreement during the calendar year the Board Member’s remuneration shall be paid pro rata temporis. 

The Board Member receives a gross annual salary of EUR 210,000.00 

 

	2.	The Board Member is further entitled to join the existing bonus program of Nabriva. The maximum bonus amounts to EUR 73,500.00, which relates to 35% of the gross annual salary of the Board Member. The amount of
bonus achieved depends on the achievement of business objectives. The bonus payment achieved is payable in the year following the year the bonus accrued. 

  

	3.	The remuneration specified in para 1 and para 2 above shall cover all of Board Member’s work, including additional services and overtime, if any. The Board Member will provide additional services or work overtime
if necessary. 

  
 - 2 - 

	4.	The remuneration specified in para 1 and para 2 also covers services rendered by the Board Member in the capacity as member of corporate bodies of affiliated companies, holding companies and other companies, on Sundays
and public holidays or otherwise in excess of statutory working hours. 

  

	5.	The Board Member is further entitled to participate in the Company’s Stock Option Plan. 

  

	6.	The remuneration specified in para 1 and para 2 above shall be reviewed by the company’s remuneration committee within the first quarter of each business year and an adjustment of the remuneration, if any, shall
retroactively come into force with effect as of the first day of the respective business year. 

 IV. REIMBURSEMENT OF
EXPENSES 
  

	1.	The Company shall reimburse the Board Member – according to its internal guidelines, as the case my be – for all necessary and appropriate personal expenses properly incurred in the fulfillment of his duties
and responsibilities pursuant to this agreement, including travel and (business) entertainment expenses. Expenses occurred by the Board Member shall be supported by receipts in line with the pertinent tax regulations, unless these regulations
provide for a lump sum assessment. 

  

	2.	The Company agrees to provide the Board Member with a company mobile phone and a company laptop at its own expense and agrees to pay for all reasonable related costs incurred, for both business and reasonable private
use. 

 V. ANNUAL VACATION, SICK LEAVE 
  

	1.	The Board Member shall be entitled to annual vacation in the amount provided by the Austrian Vacation Act, which is 25 (twenty-five) days, not considering Saturday a working day. The employment year shall commence as at
commencement of employment. Not consumed holiday can be transferred into next year’s holiday entitlement. Unconsumed holidays become time-barred after expiry of 6 months following the end of the vacation year in which the entitlement accrued.

  

	2.	When choosing his annual vacation, the Board Member shall take into consideration any needs of the Company in such way that the normal course of operation is guarantied. The time of the Board Member’s annual
vacation is subject to agreement between the Board Member and the Company. 

  

	3.	In case the Board Member is prevented from fulfilling his obligation due to illness or accident the salary according to sec III.1. shall be continued to be paid in full for three months and in the amount of 49% for
further three months. 

 VI. OBLIGATIONS, OTHER ACTIVITIES 

 

	1.	The Board Member shall provide his full working strength as well as his experience and knowledge solely to the Company. The working hours shall depend on the tasks to be fulfilled. 

 

	2.	Any other professional activity of the Board Member shall require the prior written approval of the Supervisory Board. The Board Member agrees to notify the Company in advance in writing of any secondary activity which
actually and potentially requires such approval. 

  

	3.	The commitment to activities without remuneration which cause more than an insignificant amount of work, especially functions in a Supervisory Board, the Board of an association or any similar institution shall also be
subject to prior written approval of the Supervisory Board. 

  

	4.	 The Supervisory Board may deny or revoke any approval concerning secondary activity when the activity concerned as such or in connection with any
secondary activities may give rise to an impairment of the work of the Board Member for the Company or of any other interests of the Company. In case and at the time of 

  
 - 3 - 

	 	
the termination of the employment – respectively in case of a release of duty at the time after release – the Board Member by resolution of the Supervisory Board shall resign from all
functions he took over or performed in connection with his work for the Company. 

 VII. INTELLECTUAL PROPERTY RIGHTS,

 INVENTIONS (DIENSTERFINDUNGEN) 
  

	1.	The Board Member agrees that if, in respect of Intellectual Property relating to or capable of being used in the business carried on by the Company or a company affiliated with the Company, in the course of or in any
way facilitated by virtue of his employment, the Board Member makes or discovers, or participates in the making or discovery of, Intellectual Property (including, without limitation, intellectual property falling under (i) the Patents Act
(Patentgesetz), (ii) the Patent Utility Models Act (Gebrauchsmustergesetz) and (iii) the Copyright Act (Urheberrechtsgesetz)) he shall communicate immediately full details of such Intellectual Property to the Company, and the
Company shall be the proprietor of or, if this is not legally possible, holder of any and all rights of use in the Intellectual Property. 

  

	2.	At the request and expense of the Company the Board Member shall give and supply all such information, data, drawings and assistance as is requisite to enable the Company to exploit the Intellectual Property to the best
advantage. If so requested, the Board Member shall, at the Company’s expense but without receiving payment, execute all documents and do everything necessary to vest the title to the invention, design or discovery in the Company. The Board
Member irrevocably appoints the Company to be his attorney and in his name and on his behalf to execute any documents and generally to act and to use his name for the purpose of giving to the Company (or its nominee) the full benefit of this clause.

  

	3.	The Board Member is not entitled to any payment in addition to the compensation set forth in clause III.3 of this Board Member Employment Agreement (which already reflects the making or discovery of Intellectual
Property) for the assignment of Intellectual Property as described in para 1. 

  

	4.	In respect of Intellectual Property made or discovered by the Board Member as described in para 1, the rights and obligations under this Agreement shall continue to be in force after termination of the employment and
shall be binding also upon his legal successors and representatives. 

 VII. NON ENTICEMENT CLAUSE 

Within one year after termination of employment the Board Member shall not entice from the Company other Board Members or employees of the
Company for any company he owns or holds a majority interest in or he is otherwise involved in. 
 VIII. NON COMPETITION CLAUSE 

 

	1.	During the term hereof and until the expiry of 12 (twelve months) after termination of employment, the Board Member shall neither do business for his own account nor for another’s account in the same line of
business as the Company, nor participate in a company which is primarily active in the Company’s line of business as personally liable partner or hold a position in the management board or Supervisory Board or as director, officer or authorized
agent (Prokurist) or be active in whatever manner for a company in the Company’s line of business, be itself employed, as consultant, as an employee or in any other form. The Board Member shall, however, be entitled to invest personal
assets in such a way that no controlling influence is exercised. For the purposes of this agreement, the same line of business shall mean a Company or other such entity involved in the development of pleuromutilin antibiotics. 

  
 - 4 - 

	2.	This non competition obligation shall not apply, if the Company, by its faulty conduct, has provided the Board Member with a justified cause for resigning early or terminating his employment relationship or if the
Company terminated this Agreement without justified cause or if the Board Member withdraws from his functions triggering termination of his employment relationship due to circumstances constituting a case of Change of Control. 

 

	3.	In case the Board Member violates his obligation not to entice or his obligation not to compete, he shall be liable to a contractual penalty which shall amount to the fourfold of his last gross monthly salary. The
contractual penalty shall become due upon violation of the provision set forth above. 

 IX. CONFIDENTIALITY 

 

	1.	The Board Member shall hold in the strictest confidence and not disclose to any person any of the Company’s proprietary or confidential information as to all business or operating matters both of the Company as
well as of its costumers. The Board Member shall be bound by this confidentiality obligation during the term of employment and for infinite term following the termination of employment by either party. The disclosure by the Board Member of business
or operating secrets of the Company or of its costumers to third persons without prior approval by the Company shall constitute a good cause for (i) the early revocation of the appointment of the Board Member and (ii) immediate termination of the
employment agreement by the Company. 

 X. DELIVERY OF DOCUMENTS 

 

	1.	Upon termination of this Agreement or upon revocation of the appointment of the Board Member as Management Board Member, whatever is earlier, the Board Member shall return all documents, records and other materials,
including copies, related to his work with the management board without delay and unsolicited to the Company and to destroy or irrevocably delete any information remaining with him including information on electronic data carriers. The Board Member
is not entitled to exercise a right of retention as to this documents and materials. 

  

	2.	Upon termination of the employment or upon revocation of the appointment of the Board Member, whatever is earlier, the Board Member shall also return his company car, if any, his company laptop, company mobile phone and
any other assets supplied by the Company in the course of his employment. 

 XI. FINAL PROVISIONS 

 

	1.	Save for that the Austrian Stock Corporation Act, the Company’s Articles of Association, the By-Laws for the Managing Board in its current version, if any, and this Agreement not provide otherwise, the provisions
of the Austrian Act on White Collar-Workers, as amended, shall be applicable. 

  

	2.	All claims of the Board Member against the Company must be asserted within 4 (four) months from origination or shall otherwise expire. Thus asserted claims shall be subject to the statutory period of limitations.

  

	3.	Amendments and additions to this Agreement must be made in writing to be effective, to the extent that notarization is not required. This shall also apply to a waiver of the written form requirement. 

 

	4.	This Agreement shall be governed by the law of the Republic of Austria without regard to the conflicts of laws provisions thereof. To the extent that such an agreement is legally valid, the Commercial Court competent
for Vienna, Inner City, shall have exclusive jurisdiction over this Agreement. 

  
 - 5 - 

 Vienna, February 25, 2014 
  

					
	  
 /s/ Denise Pollard-Knight
	  		  	  
 /s/ Ralf Schmid

	  
 Nabriva Therapeutics
AG,
	  		  	  
 Ralf Schmid

	Dr. Denise Pollard-Knight	  		  	

  
 - 6 - 

 ADDENDUM TO THE 

BOARD MEMBER EMPLOYMENT AGREEMENT 

between 
 Nabriva Therapeutics
AG 
 Leberstraße 20 

1112 Vienna 
 AUSTRIA 

represented by the Chair of the Supervisory Board, 

Dr. Denise Pollard-Knight 

the “Company” 
 and 

Ralf Schmid 
 Bechardgasse
16/8 
 1030 Vienna 
 AUSTRIA

 the “Board Member” 

as follows: 
  

 

 In accordance with clause XI.3 thereof, this addendum hereby amends the Board Member Employment
Agreement, effective as of March 01, 2014, between the Board Member and the Company by making the following changes: 
 1. Clause II of
the Employment Agreement is hereby deleted and replaced in its entirety by the following: 
 II. Term 

 

	 	1.	The Employment Agreement, which is intended to replace the Board Member Employment Agreement dated April 30, 2012 (the “Previous Agreement”), shall become effective as to March 01, 2014 and shall
expire on February 29, 2016 (the “Initial Term”). The Employment Agreement shall become effective with respect to a new one-year term beginning on March 01, 2016 and expiring on February 28, 2017; provided that, the
Employment Agreement shall automatically renew for additional one-year terms thereafter unless either party notifies the other in writing of such party’s intention not to renew the Employment Agreement not less than ninety (90) days prior
to the applicable term’s expiration date (any term following the Initial Term, a “Subsequent Term”). The Initial Term and each Subsequent Term shall be treated as separate and distinct from any other term; provided, however, that
(i) not consumed holidays from the Previous Agreement shall be carried forward to this Employment Agreement, and not consumed holidays from the Initial Term or any Subsequent Term shall be carried forward to the next following Subsequent Term,
to the extent that the holiday entitlement is not older than 6 months calculated from the date following the end of the vacation year in which the entitlement accrued and (ii) unless either party has timely provided a notice of non-renewal as
described above, the expiration of the Initial Term or a Subsequent Term shall not constitute a termination of this Employment Agreement for purposes of clause XI.1 (“Delivery of Documents”) hereof. 

 

	 	2.	The Supervisory Board of the Company may revoke the Board Member’s appointment for good cause within the meaning of sec 75 para 4 Austrian Stock Corporation Act (Aktiengesetz) prior to the expiry of the
Initial Term or a Subsequent Term, as applicable. In this case, the Company shall be entitled to prematurely terminate this Employment Agreement without notice. If such good cause would also justify the Board Member’s dismissal under mutatis
mutandis application of sec 27 of the Austrian Act on White Collar-Workers (Angestelltengesetz), he shall not be entitled to receive any remuneration beyond the termination date. In case the Company prematurely terminates this Employment
Agreement during the Initial Term or any Subsequent Term without justified reasons pursuant to sec 27 of the Austrian Act on White Collar-Workers, the Company shall (i) pay to the Board Member an amount equal to twelve (12) months’ salary
(based upon his salary then in effect); and (ii) provided that the Board Member is eligible for and timely elects to continue receiving group medical insurance pursuant to his current health insurance coverage, continue to pay (but in no event
longer than twelve (12) months following the Board Member’s termination date) the share of the premium for health coverage that is paid by the Company at the termination date. The payment described at (i) in the preceding sentence
shall be made in a single lump-sum payment and shall be due at the termination date without any discount. The Board Member shall not be obliged to set off such payments against remuneration gained otherwise. 

 

	 	3.	 Except as otherwise required by Austrian Law, both the Company and the Board Member are free to terminate the Board Member’s employment
relationship with the Company at any time and for any reason during any applicable term. However, if, during the Initial Term or a Subsequent Term, the Board Member’s employment is terminated by the Company without Cause (as defined below) or
by the Board Member with Good Reason (as defined below), subject to the conditions of clause II.4, the Company shall (i) continue to pay to the Board Member, in accordance with the Company’s regularly established payroll procedure, his
salary then in effect for a period of twelve (12) months; and (ii) provided that the Board Member is eligible for and timely elects to continue receiving group medical insurance pursuant to his current health insurance coverage, continue
to pay (but in no event longer than twelve (12) months following the Board Member’s termination date) the share of the premium for health coverage that is paid by the Company at the termination date. The severance benefits provided for in
this clause II.3 shall be supplemental to (but not duplicative of) the severance 

	 	
benefits provided under clause II.2 hereof in the event that a termination of employment entitles the Board Member to payments under both clause II.2 and II.3. Therefore, any amounts payable
pursuant to this clause II.3 shall be proportionately reduced by any lump sum amount payable by the Company to the Board Member pursuant to clause II.2 hereof so that, subject to the terms and conditions of this Employment Agreement, the Board
Member is entitled to no more than an amount equal to 12 months’ of his salary in effect on the termination date. Notwithstanding anything herein to the contrary, no amounts shall be payable pursuant to this clause II.3 upon a termination of
employment solely as a result of a non-renewal of the Employment Agreement for a Subsequent Term. 

 For purposes of this
clause II.3, “Cause” shall mean a finding by the Supervisory Board that the Board Member: (i) failed to perform (other than by reason of physical or mental illness or disability for a period of less than three consecutive months or in
aggregate less than twenty-six weeks) his assigned duties diligently or effectively or was negligent in the performance of these duties, provided that the Board Member was given prior written notice of such deficiencies and was granted a reasonable
opportunity of not less than thirty (30) days to correct any such deficiencies; (ii) materially breached this Employment Agreement or any other agreement between the Board Member and the Company; (iii) engaged in willful misconduct,
fraud, or embezzlement; (iv) engaged in any conduct that is materially harmful to the business, interests or reputation of the Company; or (v) was convicted of, or pleaded guilty or nolo contendere to a crime involving moral turpitude or
any felony. 
 For purposes of this clause II.3, “Good Reason” shall mean (i) the Company’s failure to pay or provide in
a timely manner any material amounts owed to the Board Member in accordance with this Employment Agreement; (ii) a material diminution in the nature or scope of the Board Member’s duties, responsibilities, or authority; (iii) the
Company’s requiring Board Member to relocate his primary office more than fifty (50) miles from Vienna, Austria; or (iv) any material breach of this Employment Agreement by the Company not otherwise covered by this paragraph;
provided, however, that the Company shall have a period of not less than fifteen (15) days to cure any act constituting Good Reason following Board Member’s delivery to the Company of written notice within sixty (60) days of the
action or omission constituting Good Reason. 
  

	 	4.	As a condition of the Board Member’s receipt of the amounts described in clause II.3, the Board Member must execute and deliver to the Company a severance and release of claims agreement in favor of the Company in
a form to be provided by the Company and must continue to comply with the Intellectual Property Rights, Inventions, Non Enticement, Non Competition and Confidentiality clauses of the Board Member’s Employment Agreement. 

2. Clauses III.1 and III.2 of the Employment Agreement are hereby deleted and replaced in their entirety by the following: 

 

	 	1.	Notwithstanding clause III.6 hereof, effective as of June 1, 2015, for his services rendered in accordance with the terms and conditions of this Employment Agreement, the Board Member shall receive a monthly gross
remuneration of EUR 19,723.57 payable fourteen times a year. Whereas the first twelve installments shall be payable at the end of each month, the 13th and 14th installments shall be due on the 31 May and 30 November of each calendar year. In the case of termination of this Agreement during the calendar year, the Board Member’s remuneration
shall be pro rata temporis. 

 Effective as of June 1, 2015, the Board Member receives a gross annual salary of
EUR 276,130. 
  

	 	2.	The Board Member is further entitled to join the existing bonus program of Nabriva. The maximum bonus amounts to 35% of the salary paid to the Board Member in the year to which the bonus relates. The amount of bonus
achieved depends on the achievement of business objectives. The bonus payment achieved is payable in the year following the year the bonus accrued. 

3. The Non Enticement Clause shall be renumbered clause VIII, the Non Competition Clause shall be renumbered clause IX, the Confidentiality
clause shall be renumbered clause X, the Delivery of Documents clause shall be renumbered clause XI, and the Final Provisions clause shall be renumbered clause XII. 

 All other regulations of the Employment Agreement remain the same. 

Vienna, July 7th, 2015 
  

			
	 /s/ Denise Pollard-Knight
	 	 /s/ Ralf Schmid

	Nabriva Therapeutics AG,	 	Ralf Schmid
	Dr. Denise Pollard-Knight

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]